Minimising Bruising After Filler and Biorevitalisation Treatments

Bruising is one of the most common and most visible side effects of injectable treatment, and it is worth addressing directly and proactively at consultation rather than treating it as an unfortunate afterthought. Small bruises at injection sites are a normal consequence of introducing a needle or cannula into vascularised tissue, not a sign that something has gone wrong — but understanding why they occur, and what increases the likelihood, allows practitioners to reduce their frequency and manage patient expectations well.

Why Bruising Occurs

Any injection carries some risk of minor injury to small blood vessels beneath the skin, and this risk rises with the number of injection points, which is one reason treatments involving multiple micro-injections — biorevitalisation and mesotherapy in particular — tend to produce more, if typically smaller, bruises than a single-point filler treatment. Small bruises generally resolve within ten to fourteen days without intervention. Active facial expression in the treated area in the hours and days after treatment can compound minor bruising by disturbing the injection site before it has settled.

Factors That Increase Risk

• Vessel fragility. Some patients have a hereditary or acquired tendency toward more fragile blood vessels; smoking is a commonly cited acquired factor.
• Clotting status. Blood-thinning medication or an underlying clotting disorder is a direct contraindication consideration for any injectable treatment and should be established during history-taking.
• High-volume, high-density product placement. Larger volumes of denser filler, such as those used for substantial lip or cheek augmentation, increase the likelihood of vessel compression and trauma at the injection site.
• Post-treatment behaviour. Smoking, alcohol, sauna or swimming pool use, and direct pressure or rubbing of the treated area in the days following treatment all add avoidable load to vessels that are still settling.

Larger, more visible bruises tend to occur in areas with thin skin and active blood flow — the lips, the periorbital area, and the upper nasolabial region are the most frequently affected. Smaller, more diffuse bruising is more typical across biorevitalisation and mesotherapy treatment areas, given the higher number of injection points involved.

Reducing the Likelihood of Bruising

A few straightforward measures, discussed with patients ahead of treatment, meaningfully reduce both the frequency and severity of bruising:

• Advise patients to avoid blood-thinning medications such as aspirin, ibuprofen and diclofenac, and to limit alcohol, in the days before treatment where medically appropriate.
• Allow patients time to settle before treatment begins rather than proceeding immediately after a rushed arrival.
• Where relevant, avoid scheduling injectable treatment during menstruation, when some patients report increased bruising tendency.
• Cannula-based technique, where clinically appropriate, generally causes less vessel trauma than repeated needle punctures across a treatment area — a relevant consideration when selecting instrumentation for biorevitalisation and multi-point treatments. Blunt-tip options such as the Needleflex cannula and other cannula formats are available in the needles and syringes range.
• A cold compress applied to the treated area for ten to fifteen minutes immediately after treatment, and repeated over the following days, is commonly recommended to limit bruise formation.

Post-Treatment Advice for Patients

Standard aftercare guidance — avoiding lying face-down in the hours after treatment, sleeping slightly elevated for a few nights, and avoiding intense exercise, sauna, swimming and sun exposure for around a week — supports healing generally and reduces the chance of aggravating a developing bruise. Where bruising is extensive or slow to resolve, topical arnica-based or heparin-containing products are sometimes used, though their absorbing action means they are generally reserved for more significant bruising rather than applied routinely, since some practitioners note they may also affect the longevity of the injected HA itself.

The Takeaway

Bruising after injectable treatment is common and usually self-limiting, but a combination of careful patient screening, appropriate instrumentation, and clear pre- and post-treatment guidance meaningfully reduces both its likelihood and its visibility — an outcome most patients notice and appreciate.

To review cannula and needle options suited to atraumatic technique, browse the needles and syringes range.